PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1485949

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1485949

Liposomes Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

PUBLISHED: May 21, 2024

PAGES: 201 Pages

DELIVERY TIME: 2-5 business days

ADD TO COMPARE

SELECT AN OPTION

Description

The global liposomes market is projected to experience significant expansion, with valuations anticipated to rise from $7.4 billion in 2024 to an impressive $10.67 billion by 2031. This represents a consistent CAGR of 5.2%, driven by advancements in drug delivery systems and the rising prevalence of chronic diseases.

Technological Breakthroughs in Liposomal Drug Delivery Systems

Innovations in liposomal drug delivery systems are revolutionizing the pharmaceutical industry. Known for their small size, biocompatibility, and chemical stability, liposomes have become integral in nanomedicine. Their ability to enhance the effectiveness of active pharmaceutical ingredients-such as prolonging shelf life and improving drug formulations-has made them a preferred choice for drug delivery.

The development of liposomal formulations for topical treatments in dermatology and other medical applications highlights the growing importance of liposome-based technologies. As technology advances, liposomal nanotechnology is expected to become a more dependable manufacturing platform, especially in public health and medical diagnostics.

Rising Demand for Liposomal Drugs

The demand for liposomal drugs is increasing due to the higher prevalence of chronic diseases, cancer, and lifestyle-related disorders such as diabetes and obesity. Liposomal drugs provide a promising solution for treating severe diseases because of their targeted delivery mechanisms and minimized side effects.

In emerging markets such as India, Mexico, and Brazil, the expanding patient population and greater awareness of health and wellness present substantial market opportunities. The increasing disposable income and economic growth in these regions further support the long-term viability of the liposomes market.

Enhancing Healthcare Infrastructure

The improvement of healthcare infrastructure and increased healthcare spending by governments in both developed and developing nations are key drivers of market growth. Better healthcare infrastructure enhances access to advanced therapeutics, thereby increasing the demand for liposomal drugs.

In countries like the United States, the high prevalence of chronic diseases, a strong healthcare infrastructure, and the presence of leading market players are contributing to market growth. For example, the American Cancer Society's 2022 report noted over 1.9 million new cancer cases and more than 609,360 cancer-related deaths, highlighting the need for advanced therapeutics.

Promising Market in Germany

Germany's extensive research and development activities in lipid pharmaceuticals, particularly for cardiovascular diseases (CVDs), are expected to further drive the liposomes market. With cardiovascular disorders being the leading cause of death in Germany-accounting for over 40% of all fatalities-the development of novel liposomal medications is crucial for reducing the prevalence and healthcare costs associated with CVDs.

Emerging Market in China

China is emerging as a key market for liposomes, driven by the increasing prevalence of chronic diseases, a growing elderly population, and market penetration by international players. The country's large patient pool and demand for new medications, such as liposomal drugs, present significant growth opportunities.

Key Distribution Channels

Pharmacies are the primary distribution channel for liposomal drugs, holding around 90.2% of the total market share in 2022. The high prevalence of chronic and skin diseases fuels the demand for liposomal drugs for therapeutic purposes. According to WHO estimates, non-communicable diseases (NCDs) cause 41 million deaths annually, with cardiovascular diseases and cancers being the leading causes.

Competitive Landscape

Leading players in the liposomes market are employing various strategies, including collaborations and the launch of new products. Notable developments include:

In January 2022, Pfizer Inc. and Acuitas Therapeutics signed a development and opportunity agreement, allowing Pfizer to develop vaccines using Acuitas' lipid nanoparticle (LNP) technology.
In October 2021, Evonik introduced a new version of LIPEX(R) liposome extruders. LIPEX(R) Flow offers a superior solution for drug designers and manufacturers, aiding the market introduction of liposomal pharmaceuticals.

The global liposomes market is set to witness considerable growth in the coming years, driven by technological advancements, increasing demand for advanced therapeutics, and strategic collaborations among key players.

Key Market Players Include

Novartis AG (Liposoma BV)
Precision NanoSystems Inc
Janssen Pharmaceutical Companies (Johnson & Johnson)
Encapsula Nano Sciences
Synpac-Kingdom Pharmaceutical Co., Ltd
Celsion GmbH
Gilead Sciences, Inc
Pacira BioSciences, Inc.
Luye Pharma Group
Sun Pharma Industries Ltd
Shanghai New Asia Pharmaceutical Co., Ltd.
ENERGY DELIVERY SOLUTIONs
Creative Biolabs
Nanovex Biotechnologies SL
Insys Therapeutics Inc
Fujifilm Holdings Corporation
Virpax Pharmaceuticals
Azaya Therapeutics
Avanti Polar Lipids, Inc.
Breath Therapeutics (Zambon company)
Getwell
Taiwan Liposome Company Ltd
Fresenius Health Care Group
Xellia Pharmaceuticals (Novo Holdings A/S)
Jazz Pharmaceuticals plc
Ipsen Biopharmaceuticals, Inc.
Baxter
GMPriority Pharma
S. G. Biopharm Pvt. Ltd

Global Liposomes market is Segmented as Below:

By Product:

Simple Liposomes
Formulated Liposomes
- Doxorubicin Liposomes
- Amphotericin B Liposomes
- Paclitaxel Liposomes
- Cytarabine Liposomes
- Irinotecan Liposomes
- Cisplatin Liposomes
- Others
Vaccines

By Application:

Drug delivery
- Cancer
- Fungal Infection
- Viral & Parasite Infection
- Others
Gene Delivery/Transfection
Contrast agents for medical imaging
Model Cell Membranes

By Distribution Channel:

Retail Sales
- Academic & Research Laboratories
- Biopharmaceutical Companies
- Clinical Research Organizations
- Others
Distributional Sales
- Hospital Pharmacies
- Retail Pharmacies
- Mail Order Pharmacies
- Drug Stores

By Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa

1. Executive Summary

1.1. Global Liposomes Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
- 2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Liposomes Market Outlook, 2018 - 2031

3.1. Global Liposomes Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
- 3.1.1. Key Highlights
  - 3.1.1.1. Simple Liposomes
  - 3.1.1.2. Formulated Liposomes
    - 3.1.1.2.1. Doxorubicin Liposomes
    - 3.1.1.2.2. Amphotericin B Liposomes
    - 3.1.1.2.3. Paclitaxel Liposomes
    - 3.1.1.2.4. Cytarabine Liposomes
    - 3.1.1.2.5. Irinotecan Liposomes
    - 3.1.1.2.6. Cisplatin Liposomes
    - 3.1.1.2.7. Others
  - 3.1.1.3. Vaccines
3.2. Global Liposomes Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
- 3.2.1. Key Highlights
  - 3.2.1.1. Drug delivery
    - 3.2.1.1.1. Cancer
    - 3.2.1.1.2. Fungal Infection
    - 3.2.1.1.3. Viral & Parasite Infection
    - 3.2.1.1.4. Others
  - 3.2.1.2. Gene Delivery/Transfection
  - 3.2.1.3. Contrast agents for medical imaging
  - 3.2.1.4. Model Cell Membranes
3.3. Global Liposomes Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 3.3.1. Key Highlights
  - 3.3.1.1. Retail Sales
    - 3.3.1.1.1. Academic & Research Laboratories
    - 3.3.1.1.2. Biopharmaceutical Companies
    - 3.3.1.1.3. Clinical Research Organizations
    - 3.3.1.1.4. Others
  - 3.3.1.2. Distributional Sales
    - 3.3.1.2.1. Hospital Pharmacies
    - 3.3.1.2.2. Retail Pharmacies
    - 3.3.1.2.3. Mail Order Pharmacies
    - 3.3.1.2.4. Drug Stores
3.4. Global Liposomes Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
- 3.4.1. Key Highlights
  - 3.4.1.1. North America
  - 3.4.1.2. Europe
  - 3.4.1.3. Asia Pacific
  - 3.4.1.4. Latin America
  - 3.4.1.5. Middle East & Africa

4. North America Liposomes Market Outlook, 2018 - 2031

4.1. North America Liposomes Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
- 4.1.1. Key Highlights
  - 4.1.1.1. Simple Liposomes
  - 4.1.1.2. Formulated Liposomes
    - 4.1.1.2.1. Doxorubicin Liposomes
    - 4.1.1.2.2. Amphotericin B Liposomes
    - 4.1.1.2.3. Paclitaxel Liposomes
    - 4.1.1.2.4. Cytarabine Liposomes
    - 4.1.1.2.5. Irinotecan Liposomes
    - 4.1.1.2.6. Cisplatin Liposomes
    - 4.1.1.2.7. Others
  - 4.1.1.3. Vaccines
4.2. North America Liposomes Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
- 4.2.1. Key Highlights
  - 4.2.1.1. Drug delivery
    - 4.2.1.1.1. Cancer
    - 4.2.1.1.2. Fungal Infection
    - 4.2.1.1.3. Viral & Parasite Infection
    - 4.2.1.1.4. Others
  - 4.2.1.2. Gene Delivery/Transfection
  - 4.2.1.3. Contrast agents for medical imaging
  - 4.2.1.4. Model Cell Membranes
4.3. North America Liposomes Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 4.3.1. Key Highlights
  - 4.3.1.1. Retail Sales
    - 4.3.1.1.1. Academic & Research Laboratories
    - 4.3.1.1.2. Biopharmaceutical Companies
    - 4.3.1.1.3. Clinical Research Organizations
    - 4.3.1.1.4. Others
  - 4.3.1.2. Distributional Sales
    - 4.3.1.2.1. Hospital Pharmacies
    - 4.3.1.2.2. Retail Pharmacies
    - 4.3.1.2.3. Mail Order Pharmacies
    - 4.3.1.2.4. Drug Stores
4.4. North America Liposomes Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 4.4.1. Key Highlights
  - 4.4.1.1. U.S. Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
  - 4.4.1.2. U.S. Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
  - 4.4.1.3. U.S. Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 4.4.1.4. Canada Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
  - 4.4.1.5. Canada Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
  - 4.4.1.6. Canada Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Liposomes Market Outlook, 2018 - 2031

5.1. Europe Liposomes Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
- 5.1.1. Key Highlights
  - 5.1.1.1. Simple Liposomes
  - 5.1.1.2. Formulated Liposomes
    - 5.1.1.2.1. Doxorubicin Liposomes
    - 5.1.1.2.2. Amphotericin B Liposomes
    - 5.1.1.2.3. Paclitaxel Liposomes
    - 5.1.1.2.4. Cytarabine Liposomes
    - 5.1.1.2.5. Irinotecan Liposomes
    - 5.1.1.2.6. Cisplatin Liposomes
    - 5.1.1.2.7. Others
  - 5.1.1.3. Vaccines
5.2. Europe Liposomes Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
- 5.2.1. Key Highlights
  - 5.2.1.1. Drug delivery
    - 5.2.1.1.1. Cancer
    - 5.2.1.1.2. Fungal Infection
    - 5.2.1.1.3. Viral & Parasite Infection
    - 5.2.1.1.4. Others
  - 5.2.1.2. Gene Delivery/Transfection
  - 5.2.1.3. Contrast agents for medical imaging
  - 5.2.1.4. Model Cell Membranes
5.3. Europe Liposomes Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 5.3.1. Key Highlights
  - 5.3.1.1. Retail Sales
    - 5.3.1.1.1. Academic & Research Laboratories
    - 5.3.1.1.2. Biopharmaceutical Companies
    - 5.3.1.1.3. Clinical Research Organizations
    - 5.3.1.1.4. Others
  - 5.3.1.2. Distributional Sales
    - 5.3.1.2.1. Hospital Pharmacies
    - 5.3.1.2.2. Retail Pharmacies
    - 5.3.1.2.3. Mail Order Pharmacies
    - 5.3.1.2.4. Drug Stores
5.4. Europe Liposomes Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 5.4.1. Key Highlights
  - 5.4.1.1. Germany Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
  - 5.4.1.2. Germany Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
  - 5.4.1.3. Germany Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.4.1.4. U.K. Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
  - 5.4.1.5. U.K. Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
  - 5.4.1.6. U.K. Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.4.1.7. France Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
  - 5.4.1.8. France Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
  - 5.4.1.9. France Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.4.1.10. Italy Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
  - 5.4.1.11. Italy Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
  - 5.4.1.12. Italy Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.4.1.13. Turkey Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
  - 5.4.1.14. Turkey Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
  - 5.4.1.15. Turkey Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.4.1.16. Russia Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
  - 5.4.1.17. Russia Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
  - 5.4.1.18. Russia Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.4.1.19. Rest of Europe Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
  - 5.4.1.20. Rest of Europe Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
  - 5.4.1.21. Rest of Europe Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Liposomes Market Outlook, 2018 - 2031

6.1. Asia Pacific Liposomes Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
- 6.1.1. Key Highlights
  - 6.1.1.1. Simple Liposomes
  - 6.1.1.2. Formulated Liposomes
    - 6.1.1.2.1. Doxorubicin Liposomes
    - 6.1.1.2.2. Amphotericin B Liposomes
    - 6.1.1.2.3. Paclitaxel Liposomes
    - 6.1.1.2.4. Cytarabine Liposomes
    - 6.1.1.2.5. Irinotecan Liposomes
    - 6.1.1.2.6. Cisplatin Liposomes
    - 6.1.1.2.7. Others
  - 6.1.1.3. Vaccines
6.2. Asia Pacific Liposomes Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
- 6.2.1. Key Highlights
  - 6.2.1.1. Drug delivery
    - 6.2.1.1.1. Cancer
    - 6.2.1.1.2. Fungal Infection
    - 6.2.1.1.3. Viral & Parasite Infection
    - 6.2.1.1.4. Others
  - 6.2.1.2. Gene Delivery/Transfection
  - 6.2.1.3. Contrast agents for medical imaging
  - 6.2.1.4. Model Cell Membranes
6.3. Asia Pacific Liposomes Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 6.3.1. Key Highlights
  - 6.3.1.1. Retail Sales
    - 6.3.1.1.1. Academic & Research Laboratories
    - 6.3.1.1.2. Biopharmaceutical Companies
    - 6.3.1.1.3. Clinical Research Organizations
    - 6.3.1.1.4. Others
  - 6.3.1.2. Distributional Sales
    - 6.3.1.2.1. Hospital Pharmacies
    - 6.3.1.2.2. Retail Pharmacies
    - 6.3.1.2.3. Mail Order Pharmacies
    - 6.3.1.2.4. Drug Stores
- 6.3.2. BPS Analysis/Market Attractiveness Analysis
6.4. Asia Pacific Liposomes Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 6.4.1. Key Highlights
  - 6.4.1.1. China Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
  - 6.4.1.2. China Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
  - 6.4.1.3. China Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.4.1.4. Japan Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
  - 6.4.1.5. Japan Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
  - 6.4.1.6. Japan Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.4.1.7. South Korea Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
  - 6.4.1.8. South Korea Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
  - 6.4.1.9. South Korea Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.4.1.10. India Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
  - 6.4.1.11. India Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
  - 6.4.1.12. India Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.4.1.13. Southeast Asia Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
  - 6.4.1.14. Southeast Asia Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
  - 6.4.1.15. Southeast Asia Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.4.1.16. Rest of Asia Pacific Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
  - 6.4.1.17. Rest of Asia Pacific Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
  - 6.4.1.18. Rest of Asia Pacific Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Liposomes Market Outlook, 2018 - 2031

7.1. Latin America Liposomes Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
- 7.1.1. Key Highlights
  - 7.1.1.1. Simple Liposomes
  - 7.1.1.2. Formulated Liposomes
    - 7.1.1.2.1. Doxorubicin Liposomes
    - 7.1.1.2.2. Amphotericin B Liposomes
    - 7.1.1.2.3. Paclitaxel Liposomes
    - 7.1.1.2.4. Cytarabine Liposomes
    - 7.1.1.2.5. Irinotecan Liposomes
    - 7.1.1.2.6. Cisplatin Liposomes
    - 7.1.1.2.7. Others
  - 7.1.1.3. Vaccines
7.2. Latin America Liposomes Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
- 7.2.1. Key Highlights
  - 7.2.1.1. Drug delivery
    - 7.2.1.1.1. Cancer
    - 7.2.1.1.2. Fungal Infection
    - 7.2.1.1.3. Viral & Parasite Infection
    - 7.2.1.1.4. Others
  - 7.2.1.2. Gene Delivery/Transfection
  - 7.2.1.3. Contrast agents for medical imaging
  - 7.2.1.4. Model Cell Membranes
7.3. Latin America Liposomes Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 7.3.1. Key Highlights
  - 7.3.1.1. Retail Sales
    - 7.3.1.1.1. Academic & Research Laboratories
    - 7.3.1.1.2. Biopharmaceutical Companies
    - 7.3.1.1.3. Clinical Research Organizations
    - 7.3.1.1.4. Others
  - 7.3.1.2. Distributional Sales
    - 7.3.1.2.1. Hospital Pharmacies
    - 7.3.1.2.2. Retail Pharmacies
    - 7.3.1.2.3. Mail Order Pharmacies
    - 7.3.1.2.4. Drug Stores
- 7.3.2. BPS Analysis/Market Attractiveness Analysis
7.4. Latin America Liposomes Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 7.4.1. Key Highlights
  - 7.4.1.1. Brazil Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
  - 7.4.1.2. Brazil Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
  - 7.4.1.3. Brazil Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 7.4.1.4. Mexico Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
  - 7.4.1.5. Mexico Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
  - 7.4.1.6. Mexico Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 7.4.1.7. Argentina Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
  - 7.4.1.8. Argentina Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
  - 7.4.1.9. Argentina Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 7.4.1.10. Rest of Latin America Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
  - 7.4.1.11. Rest of Latin America Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
  - 7.4.1.12. Rest of Latin America Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Liposomes Market Outlook, 2018 - 2031

8.1. Middle East & Africa Liposomes Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
- 8.1.1. Key Highlights
  - 8.1.1.1. Simple Liposomes
  - 8.1.1.2. Formulated Liposomes
    - 8.1.1.2.1. Doxorubicin Liposomes
    - 8.1.1.2.2. Amphotericin B Liposomes
    - 8.1.1.2.3. Paclitaxel Liposomes
    - 8.1.1.2.4. Cytarabine Liposomes
    - 8.1.1.2.5. Irinotecan Liposomes
    - 8.1.1.2.6. Cisplatin Liposomes
    - 8.1.1.2.7. Others
  - 8.1.1.3. Vaccines
8.2. Middle East & Africa Liposomes Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
- 8.2.1. Key Highlights
  - 8.2.1.1. Drug delivery
    - 8.2.1.1.1. Cancer
    - 8.2.1.1.2. Fungal Infection
    - 8.2.1.1.3. Viral & Parasite Infection
    - 8.2.1.1.4. Others
  - 8.2.1.2. Gene Delivery/Transfection
  - 8.2.1.3. Contrast agents for medical imaging
  - 8.2.1.4. Model Cell Membranes
8.3. Middle East & Africa Liposomes Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 8.3.1. Key Highlights
  - 8.3.1.1. Retail Sales
    - 8.3.1.1.1. Academic & Research Laboratories
    - 8.3.1.1.2. Biopharmaceutical Companies
    - 8.3.1.1.3. Clinical Research Organizations
    - 8.3.1.1.4. Others
  - 8.3.1.2. Distributional Sales
    - 8.3.1.2.1. Hospital Pharmacies
    - 8.3.1.2.2. Retail Pharmacies
    - 8.3.1.2.3. Mail Order Pharmacies
    - 8.3.1.2.4. Drug Stores
- 8.3.2. BPS Analysis/Market Attractiveness Analysis
8.4. Middle East & Africa Liposomes Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 8.4.1. Key Highlights
  - 8.4.1.1. GCC Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
  - 8.4.1.2. GCC Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
  - 8.4.1.3. GCC Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.4.1.4. South Africa Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
  - 8.4.1.5. South Africa Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
  - 8.4.1.6. South Africa Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.4.1.7. Egypt Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
  - 8.4.1.8. Egypt Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
  - 8.4.1.9. Egypt Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.4.1.10. Nigeria Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
  - 8.4.1.11. Nigeria Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
  - 8.4.1.12. Nigeria Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.4.1.13. Rest of Middle East & Africa Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
  - 8.4.1.14. Rest of Middle East & Africa Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
  - 8.4.1.15. Rest of Middle East & Africa Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. By Product vs by Application Heat map
9.2. Company Market Share Analysis, 2023
9.3. Competitive Dashboard
9.4. Company Profiles
- 9.4.1. Novartis AG (Liposoma BV)
  - 9.4.1.1. Company Overview
  - 9.4.1.2. Product Portfolio
  - 9.4.1.3. Financial Overview
  - 9.4.1.4. Business Strategies and Development
- 9.4.2. Precision NanoSystems Inc
  - 9.4.2.1. Company Overview
  - 9.4.2.2. Product Portfolio
  - 9.4.2.3. Financial Overview
  - 9.4.2.4. Business Strategies and Development
- 9.4.3. Janssen Pharmaceutical Companies (Johnson & Johnson
  - 9.4.3.1. Company Overview
  - 9.4.3.2. Product Portfolio
  - 9.4.3.3. Financial Overview
  - 9.4.3.4. Business Strategies and Development
- 9.4.4. Encapsula Nano Sciences
  - 9.4.4.1. Company Overview
  - 9.4.4.2. Product Portfolio
  - 9.4.4.3. Financial Overview
  - 9.4.4.4. Business Strategies and Development
- 9.4.5. Synpac-Kingdom Pharmaceutical Co., Ltd
  - 9.4.5.1. Company Overview
  - 9.4.5.2. Product Portfolio
  - 9.4.5.3. Financial Overview
  - 9.4.5.4. Business Strategies and Development
- 9.4.6. Celsion GmbH
  - 9.4.6.1. Company Overview
  - 9.4.6.2. Product Portfolio
  - 9.4.6.3. Financial Overview
  - 9.4.6.4. Business Strategies and Development
- 9.4.7. Gilead Sciences, Inc
  - 9.4.7.1. Company Overview
  - 9.4.7.2. Product Portfolio
  - 9.4.7.3. Financial Overview
  - 9.4.7.4. Business Strategies and Development
- 9.4.8. Pacira BioSciences, Inc.
  - 9.4.8.1. Company Overview
  - 9.4.8.2. Product Portfolio
  - 9.4.8.3. Financial Overview
  - 9.4.8.4. Business Strategies and Development
- 9.4.9. Luye Pharma Group
  - 9.4.9.1. Company Overview
  - 9.4.9.2. Product Portfolio
  - 9.4.9.3. Financial Overview
  - 9.4.9.4. Business Strategies and Development
- 9.4.10. Sun Pharma Industries Ltd
  - 9.4.10.1. Company Overview
  - 9.4.10.2. Product Portfolio
  - 9.4.10.3. Financial Overview
  - 9.4.10.4. Business Strategies and Development

10. Appendix

10.1.Research Methodology
10.2.Report Assumptions
10.3.Acronyms and Abbreviations

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ